Talus Bioscience and PRISM BioLab have agreed to join forces with the aim of accelerating the discovery and development of novel small-molecule modulators of transcription factor (TF) and protein-protein interaction (PPI) targets. The collaboration combines Talus Bio’s regulome profiling and AI-guided drug discovery platform with PRISM’s chemistry platform. “This collaboration gives us an unprecedented opportunity […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!